The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Oncolytic viruses: a new class of immunotherapy drugs
Open accessAbstract
Oncolytic viruses represent a new class of therapeutic agents that promote anti-tumour responses through a dual mechanism of action that is dependent on selective tumour cell killing and the induction of systemic anti-tumour immunity. The molecular and cellular mechanisms of action are not fully elucidated but are likely to depend on viral replication within transformed cells, induction of primary cell death, interaction with tumour cell antiviral elements and initiation of innate and adaptive anti-tumour immunity. A variety of native and genetically modified viruses have been developed as oncolytic agents, and the approval of the first oncolytic virus by the US Food and Drug Administration (FDA) is anticipated in the near future. This Review provides a comprehensive overview of the basic biology supporting oncolytic viruses as cancer therapeutic agents, describes oncolytic viruses in advanced clinical trials and discusses the unique challenges in the development of oncolytic viruses as a new class of drugs for the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Autophagy and Viruses: Adversaries or Allies?
Dong, X., & Levine, B. (2013) · Journal of Innate Immunity · doi:10.1159/000346388 · Cited by 4,430
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Self-citationSelective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
(2012) · Hepatogastroenterology · doi:10.5754/hge12458 · Cited by 1,977
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
The human CD46 molecule is a receptor for measles virus (Edmonston strain)
Dörig, R. E., Marcil, A., Chopra, A., & Richardson, C. D. (1993) · Cell · doi:10.1016/0092-8674(93)80071-l · Cited by 1,033
Meurs, E., Chong, K., Galabru, J., Thomas, N. S. B., Kerr, I. M., Williams, B. R. G., & Hovanessian, A. G. (1990) · Cell · doi:10.1016/0092-8674(90)90374-n · Cited by 1,017
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Differential macrophage programming in the tumor microenvironment
Ruffell, B., Affara, N. I., & Coussens, L. M. (2012) · Trends in Immunology · doi:10.1016/j.it.2011.12.001 · Cited by 860
HSV-1 ICP34.5 Confers Neurovirulence by Targeting the Beclin 1 Autophagy Protein
Orvedahl, A., Alexander, D., Tallóczy, Z., Sun, Q., Wei, Y., Zhang, W., Burns, D., Leib, D. A., & Levine, B. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2006.12.001 · Cited by 857
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N., & Curiel, D. T. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9706-9713.1998 · Cited by 767
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
He, B., Gross, M., & Roizman, B. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.843 · Cited by 751
Ljunggren, H. G., & Kärre, K. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.6.1745 · Cited by 736
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S., & White, E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7742 · Cited by 660
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus
Strong, J. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3351 · Cited by 552
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
Self-citationChina Approves World's First Oncolytic Virus Therapy For Cancer Treatment
Garber, K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj111 · Cited by 489
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
A Strategy To Estimate Unknown Viral Diversity in Mammals
Anthony, S. J., Epstein, J. H., Murray, K. A., Navarrete-Macias, I., Zambrana-Torrelio, C. M., Solovyov, A., Ojeda-Flores, R., Arrigo, N. C., Islam, A., Ali Khan, S., et al. (2013) · mBio · doi:10.1128/mbio.00598-13 · Cited by 415
REGRESSION OF BURKITT'S LYMPHOMA IN ASSOCIATION WITH MEASLES INFECTION
Bluming, A., & Ziegler, J. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92086-1 · Cited by 410
O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E., & Francis, G. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018021 · Cited by 409
Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme
Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.016 · Cited by 407
McKee, T. D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J. P., Bawendi, M. G., Boucher, Y., Breakefield, X. O., & Jain, R. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2242 · Cited by 397
Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A., & Buller, R. M. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.27.15974 · Cited by 386
DeWeese, T. L., van der Poel, H. G., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U. M., DeJong, R., Detorie, N. A., Rodríguez, R., et al. (2001) · PubMed · Cited by 385
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Intergeneric poliovirus recombinants for the treatment of malignant glioma
Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H., & Wimmer, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6803 · Cited by 363
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605496103 · Cited by 357
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353
Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003208 · Cited by 342
Harrow, S., Papanastassiou, V, Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. M., & Rampling, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302289 · Cited by 342
Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R., Louis, D. N., Bartus, R. T., Hochberg, F. H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 339
Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., & Kim, J. H. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.9-1323 · Cited by 337
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Tjuvajev, J. G., Finn, R., Watanabe, K. A., Joshi, R., Oku, T., Kennedy, J. D., Beattie, B. J., Koutcher, J. A., Larson, S. M., & Blasberg, R. G. (1996) · PubMed · Cited by 332
Dingli, D., Peng, K.-W., Harvey, M. E., Greipp, P. R., O'Connor, M. K., Cattaneo, R., Morris, J. C., & Russell, S. J. (2004) · Blood · doi:10.1182/blood-2003-07-2233 · Cited by 320
High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus
Anderson, B. D., Nakamura, T., Russell, S. J., & Peng, K.-W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0884 · Cited by 315
Freytag, S. O., Khil, M. S., Stricker, H. J., et al. (2002) · PubMed · Cited by 310
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
Kim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303
In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial
Herman, J. R., Adler, H. L., Aguilar-Cordova, E., Rojas-Martinez, A., Woo, S., Timme, T. L., Wheeler, T. M., Thompson, T. C., & Scardino, P. T. (1999) · Human Gene Therapy · doi:10.1089/10430349950018229 · Cited by 301
Carlsten, M., Norell, H., Bryceson, Y. T., Poschke, I., Schedvins, K., Ljunggren, H.-G., Kiessling, R., & Malmberg, K.-J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901226 · Cited by 283
Freytag, S. O., Stricker, H. J., Pegg, J., Paielli, D. L., Pradhan, D. G., Peabody, J. O., de Peralta‐Venturina, M., Xia, X., Brown, S., Lü, M., et al. (2003) · PubMed · Cited by 271
Protein kinase R reveals an evolutionary model for defeating viral mimicry
Elde, N. C., Child, S. J., Geballe, A. P., & Malik, H. S. (2009) · Nature · doi:10.1038/nature07529 · Cited by 260
Cellular and Humoral Immunity against Vaccinia Virus Infection of Mice
Xu, R., Johnson, A. J., Liggitt, D., & Bevan, M. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6265 · Cited by 260
Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions
Zamarin, D., & Palese, P. (2012) · Future Microbiology · doi:10.2217/fmb.12.4 · Cited by 254
(1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4660 · Cited by 247
Shafren, D. R., Dorahy, D. J., Ingham, R. A., Burns, G. F., & Barry, R. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.6.4736-4743.1997 · Cited by 243
Ramesh, N., Ge, Y., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D.-C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1059 · Cited by 242
Xia, Z.-J., Chang, J.-H., Zhang, L., et al. (2004) · PubMed · Cited by 241
Small, E. J., Carducci, M. A., Burke, J. M., Rodriguez, R., Fong, L., van Ummersen, L., Yu, D. C., Aimi, J., Ando, D., Working, P., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.011 · Cited by 241
CRAWFORD, J. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92370-8 · Cited by 239
Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1
Farassati, F., Yang, A.-D., & Lee, P. W. K. (2001) · Nature Cell Biology · doi:10.1038/35087061 · Cited by 236
Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228
Targets and mechanisms for the regulation of translation in malignant transformation
Clemens, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207544 · Cited by 223
Poppers, J., Mulvey, M., Khoo, D., & Mohr, I. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11215-11221.2000 · Cited by 223
Miyamoto, S., Inoue, H., Nakamura, T., Yamada, M., Sakamoto, C., Urata, Y., Okazaki, T., Marumoto, T., Takahashi, A., Takayama, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3185 · Cited by 222
Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection
Morizono, K., Xie, Y., Ringpis, G.-E., Johnson, M., Nassanian, H., Lee, B., Wu, L., & Chen, I. S. Y. (2005) · Nature Medicine · doi:10.1038/nm1192 · Cited by 220
Kaufman, H. L., & Bines, S. D. (2010) · Future Oncology · doi:10.2217/fon.10.66 · Cited by 209
Self-citationDi Paolo, N. C., Miao, E. A., Iwakura, Y., Murali-Krishna, K., Aderem, A., Flavell, R. A., Papayannopoulou, T., & Shayakhmetov, D. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.015 · Cited by 207
Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein
Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., & Wold, W. S. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6147-6155.2000 · Cited by 206
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Alvarez-Breckenridge, C. A., Yu, J., Price, R., Wojton, J., Pradarelli, J., Mao, H., Wei, M., Wang, Y., He, S., Hardcastle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.3013 · Cited by 205
Guedan, S., Rojas, J. J., Gros, A., Mercade, E., Cascallo, M., & Alemany, R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.79 · Cited by 204
Mader, E. K., Maeyama, Y., Lin, Y., Butler, G. W., Russell, H. M., Galanis, E., Russell, S. J., Dietz, A. B., & Peng, K.-W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1292 · Cited by 204
Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus
Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J., & Thorne, S. H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040353 · Cited by 203
[The European directorate for the quality of medicines].
Artiges, A. (2001) · PubMed · Cited by 201
Dependence of Adenovirus Infectivity on Length of the Fiber Shaft Domain
Shayakhmetov, D. M., & Lieber, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.22.10274-10286.2000 · Cited by 197
ICAM-1 as a molecular target for triple negative breast cancer
Guo, P., Huang, J., Wang, L., Jia, D., Yang, J., Dillon, D. A., Zurakowski, D., Mao, H., Moses, M. A., & Auguste, D. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408556111 · Cited by 192
The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon
Prestwich, R. J., Errington, F., Diaz, R. M., Pandha, H. S., Harrington, K. J., Melcher, A. A., & Vile, R. G. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.135 · Cited by 191
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Kanerva, A., Nokisalmi, P., Diaconu, I., Koski, A., Cerullo, V., Liikanen, I., Tähtinen, S., Oksanen, M., Heiskanen, R., Pesonen, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2546 · Cited by 177
Potentiating Cancer Immunotherapy Using an Oncolytic Virus
Bridle, B. W., Stephenson, K. B., Boudreau, J. E., Koshy, S., Kazdhan, N., Pullenayegum, E., Brunellière, J., Bramson, J. L., Lichty, B. D., & Wan, Y. (2010) · Molecular Therapy · doi:10.1038/mt.2010.98 · Cited by 176
Boviatsis, E., Park, J., Sena‐Esteves, M., Kramm, C. M., Chase, M., Efird, J. T., Wei, M., Breakefield, X. O., & Chiocca, E. A. (1994) · PubMed · Cited by 175
Mansour, M., Palese, P., & Zamarin, D. (2011) · Journal of Virology · doi:10.1128/jvi.01537-10 · Cited by 168
Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy
Willmon, C., Harrington, K., Kottke, T., Prestwich, R., Melcher, A., & Vile, R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.194 · Cited by 167
Geletneky, K., Huesing, J., Rommelaere, J., Schlehofer, J. R., Leuchs, B., Dahm, M., Krebs, O., Doeberitz, M. V. K., Huber, B., & Hajda, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-99 · Cited by 159
Shafren, D. R., Au, G. G., Nguyen, T. P., Newcombe, N. G., Haley, E. S., Beagley, L., Johansson, E., Hersey, P., & Barry, R. D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0690-3 · Cited by 158
Piazza, M., Mader, C., Geletneky, K., y Calle, M. H., Weber, E., Schlehofer, J. R., Deleu, L., & Rommelaere, J. (2007) · Journal of Virology · doi:10.1128/jvi.02601-06 · Cited by 156
Matrix Metalloproteinases-1 and -8 Improve the Distribution and Efficacy of an Oncolytic Virus
Mok, W., Boucher, Y., & Jain, R. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-3107 · Cited by 153
Rudin, C. M., Poirier, J. T., Senzer, N. N., Stephenson, J., Loesch, D. M., Burroughs, K. D., Reddy, P. S., Hann, C. L., & Hallenbeck, P. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1706 · Cited by 153
Schietinger, A., Philip, M., Liu, R. B., Schreiber, K., & Schreiber, H. W. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20092450 · Cited by 150
Kaufman, H. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24624 · Cited by 146
Self-citationNeuman, E., Flemington, E. K., Sellers, W. R., & Kaelin, W. G. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6607 · Cited by 144
Poliovirus receptor CD155-targeted oncolysis of glioma
Merrill, M. K., Bernhardt, G., Sampson, J. H., Wikstrand, C. J., Bigner, D. D., & Gromeier, M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000577 · Cited by 141
Cyclin D1 Is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma
Yu, Z., Weinberger, P., Haffty, B. G., Sasaki, C. T., Zerillo, C. A., Joe, J. K., Kowalski, D. P., Dziura, J. D., Camp, R. L., Rimm, D. L., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1160.11.3 · Cited by 139
Scholl, S., Balloul, J., Goc, G. L., Bizouarne, N., Schatz, C., Kiény, M. P., von Mensdorff‐Pouilly, S., Vincent‐Salomon, A., Deneux, L., Tartour, É., et al. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200009000-00007 · Cited by 129
Herpes Simplex Virus Type 2 ICP47 Inhibits Human TAP but Not Mouse TAP
Tomazin, R., van Schoot, N. E. G., Goldsmith, K., Jugovic, P., Sempé, P., Früh, K., & Johnson, D. C. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2560-2563.1998 · Cited by 125
Lolkema, M. P., Arkenau, H., Harrington, K. J., Roxburgh, P., Morrison, R., Roulstone, V., Twigger, K. R., Coffey, M. C., Mettinger, K. L., Gill, G. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2159 · Cited by 125
Aghi, M. K., Chou, T., Suling, K. M., Breakefield, X. O., & Chiocca, E. A. (1999) · PubMed · Cited by 124
Uchida, H., Marzulli, M., Nakano, K., Goins, W. F., Chan, J., Hong, C., Mazzacurati, L., Yoo, J. Y., Haseley, A., Nakashima, H., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.211 · Cited by 123
Li, J., Liu, H., Xr, Z., Xu, J.-P., Hu, W.-K., Liang, M., Chen, S.-Y., Hu, F., & Chu, D.-T. (2008) · Gene Therapy · doi:10.1038/gt.2008.179 · Cited by 122
Sova, P., Ren, X.-W., Ni, S., Bernt, K. M., Mi, J., Kiviat, N., & Lieber, A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.008 · Cited by 121
Post, D. E., Sandberg, E. M., Kyle, M. M., Devi, N. S., Brat, D. J., Xu, Z., Tighiouart, M., & Meir, E. G. V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3244 · Cited by 119
Eck, S. L., Alavi, J. Β., Alavi, A. A., Davis, A. R., Hackney, D. B., Judy, K. D., Mollman, J. E., Phillips∥, P. C., Wheeldon, E. B., & Wilson, J. M. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.12-1465 · Cited by 110
Foloppe, J., Kintz, J., Futin, N., Findeli, A., Cordier, P., Schlesinger, Y., Hoffmann, C., Tosch, C., Balloul, J.-M., & Erbs, P. (2008) · Gene Therapy · doi:10.1038/gt.2008.82 · Cited by 110
Getting oncolytic virus therapies off the ground
Bell, J. C., Lichty, B. D., & Stojdl, D. F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00170-3 · Cited by 109
Merrill, M. K., & Gromeier, M. (2006) · Journal of Virology · doi:10.1128/jvi.00243-06 · Cited by 109
MicroRNA-sensitive Oncolytic Measles Viruses for Cancer-specific Vector Tropism
Leber, M. F., Bossow, S., Léonard, V. H. J., Zaoui, K., Grossardt, C., Frenzke, M. E., Miest, T. S., Sawall, S., Cattaneo, R., Kalle, C. V., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.55 · Cited by 108
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma
Au, G. G., Lincz, L. F., Enno, A., & Shafren, D. R. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06550.x · Cited by 102
Brown, S. M., MacLean, A. R., McKie, E. A., & Harland, J. (1997) · Journal of Virology · doi:10.1128/jvi.71.12.9442-9449.1997 · Cited by 99
Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
Elankumaran, S., Chavan, V., Qiao, D., Raghunath, S., Moorkanat, G., Biswas, M., & Samal, S. K. (2010) · Journal of Virology · doi:10.1128/jvi.01553-09 · Cited by 95
Ganesh, S., Gonzalez-Edick, M., Gibbons, D., Roey, M. V., & Jooss, K. U. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4732 · Cited by 95
Bischoff, J. R., & Samuel, C. E. (1989) · Virology · doi:10.1016/0042-6822(89)90112-8 · Cited by 94
The Complement Response Against an Oncolytic Virus Is Species-Specific in Its Activation Pathways
Wakimoto, H., Ikeda, K., Abé, T., et al. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0547 · Cited by 93
Teh, B. S., Aguilar-Cordova, E., Kernen, K. M., CHOU, C. C., Shalev, M., Vlachaki, M. T., Miles, B. J., Kadmon, D., Mai, W.-Y., Caillouet, J., et al. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01692-3 · Cited by 92
Springfeld, C., von Messling, V., Frenzke, M. E., Ungerechts, G., Buchholz, C. J., & Cattaneo, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0538 · Cited by 90
Kim, K. H., Dmitriev, I. P., Saddekni, S., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.06.003 · Cited by 87
Chang, J., Zhao, X., Wu, X., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7913 · Cited by 87
Effect of hypoxia on Ad5 infection, transgene expression and replication
Shen, B. H., & Hermiston, T. W. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302448 · Cited by 86
Morrison, J., Briggs, S. S., Green, N. H., Fisher, K. D., Šubr, V., Ulbrich, K., Kehoe, S. T., & Seymour, L. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300363 · Cited by 86
Merrill, M. K., Dobrikova, E. Y., & Gromeier, M. (2006) · Journal of Virology · doi:10.1128/jvi.80.7.3147-3156.2006 · Cited by 82
Martin‐Moe, S., Lim, F. J., Wong, R. L., Sreedhara, A., Sundaram, J., & Sane, S. U. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22545 · Cited by 80
Schirrmacher, V. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000223 · Cited by 80
Tesfay, M. Z., Kirk, A. C., Hadac, E. M., Griesmann, G. E., Federspiel, M. J., Barber, G. N., Henry, S. M., Peng, K.-W., & Russell, S. J. (2013) · Journal of Virology · doi:10.1128/jvi.02832-12 · Cited by 79
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer
Nguyen, A., Ho, L., & Wan, Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00145 · Cited by 77
Kaufman, H. L., Cohen, S., Cheung, K., DeRaffele, G., Mitcham, J., Moroziewicz, D. N., Schlom, J., & Hesdorffer, C. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.239 · Cited by 77
Self-citationClinical utility of recombinant adenoviral human p53 gene therapy: current perspectives
Chen, G., Zhang, S. J., He, X., Liu, S., Ma, C., & Zou, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s50483 · Cited by 76
Bilbao, R., Bustos, M., Alzuguren, P., Pajares, M. J., Droździk, M., Qian, C., & Prìeto, J. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301312 · Cited by 74
Neuman, E., Flemington, E. K., Sellers, W. R., et al. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6607-6615.1994 · Cited by 73
Pharmacologic and Chemical Adjuvants in Tumor Virotherapy
Alvarez-Breckenridge, C. A., Kaur, B., & Chiocca, E. A. (2009) · Chemical Reviews · doi:10.1021/cr900048k · Cited by 60
Vesicular Egress of Non-Enveloped Lytic Parvoviruses Depends on Gelsolin Functioning
Bär, S., Daeffler, L., Rommelaere, J., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000126 · Cited by 60
Immunological Effects of a Tumor Necrosis Factor Alpha–Armed Oncolytic Adenovirus
Hirvinen, M., Rajecki, M., Kapanen, M. K., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.069 · Cited by 59
Ingemarsdotter, C. K., Baird, S. K., Connell, C. M., Öberg, D., Halldén, G., & McNeish, I. A. (2010) · Oncogene · doi:10.1038/onc.2010.335 · Cited by 56
Minuk, G. Y., Rascanin, N., Paul, R. W., Lee, P. W. K., Buchan, K., & Kelly, J. K. (1987) · Journal of Hepatology · doi:10.1016/s0168-8278(87)80054-5 · Cited by 56
Assessing oncologic benefit in clinical trials of immunotherapy agents
Hales, R. K., Banchereau, J., Ribas, A., Tarhini, A. A., Weber, J. S., Fox, B. A., & Drake, C. G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq048 · Cited by 55
Harland, J., Dunn, P., Cameron, E., Conner, J., & Brown, S. M. (2003) · Journal of NeuroVirology · doi:10.1080/13550280390218788 · Cited by 52
Berger, C., Xuereb, S. M., Johnson, D. C., Watanabe, K. S., Kiem, H., Greenberg, P. D., & Riddell, S. R. (2000) · Journal of Virology · doi:10.1128/.74.10.4465-4473.2000 · Cited by 47
Grekova, S. P., Aprahamian, M., Giese, N. A., Schmitt, S., Giese, T., Falk, C. S., Daeffler, L., Cziepluch, C., Rommelaere, J., & Raykov, Z. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.12.13455 · Cited by 44
Human T-Cell Responses to Vaccinia Virus Envelope Proteins
Tang, J., Murtadha, M., Schnell, M. J., Eisenlohr, L. C., Hooper, J. W., & Flomenberg, P. R. (2006) · Journal of Virology · doi:10.1128/jvi.00601-06 · Cited by 43
Puzanov, I. J., Milhem, M. M., Andtbacka, R. H. I., Minor, D. R., Hamid, O., Ai, L., Chou, J., & Kaufman, H. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9063 · Cited by 43
Self-citationHost mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
Fournier, P., Schirrmacher, V., & Apostolidis, L. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.5.1009 · Cited by 37
Cuddington, B., & Mossman, K. L. (2014) · Journal of Virology · doi:10.1128/jvi.00849-14 · Cited by 32
Bian, H., Wilden, H., Fournier, P., Peeters, B. P. H., & Schirrmacher, V. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.6.1359 · Cited by 31
Correction: Oncolytic and Gene Therapy Using HYPR-Ad-IL4
(2007) · Cancer Research · doi:10.1158/0008-5472.can-67-17-cor1 · Cited by 26
Haddad, D. R., Chen, C., Carlin, S., Silberhumer, G. R., Chen, N. G., Zhang, Q., Longo, V. A., Carpenter, S. G., Mittra, A., Carson, J. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041647 · Cited by 25
Takagi‐Kimura, M., Yamano, T., Tamamoto, A., Okamura, N., Okamura, H., Hashimoto‐Tamaoki, T., Tagawa, M., Kasahara, N., & Kubo, S. (2013) · Cancer Science · doi:10.1111/cas.12267 · Cited by 24
Eisenberg, D. P., Carpenter, S. G., Adusumilli, P. S., Chan, M.-K., Hendershott, K. J., Yu, Z., & Fong, Y. (2010) · Surgery · doi:10.1016/j.surg.2010.05.005 · Cited by 24
[Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer].
Yuan, Z. Y., Zhang, L., Li, S., et al. (2003) · PubMed · Cited by 23
Herpes simplex virus 2 ICP34.5 confers neurovirulence by regulating the type I interferon response
Davis, K. L., Korom, M., & Morrison, L. A. (2014) · Virology · doi:10.1016/j.virol.2014.08.015 · Cited by 20
Managing Unexpected Events in the Manufacturing of Biologic Medicines
Grampp, G. E., & Ramanan, S. (2013) · BioDrugs · doi:10.1007/s40259-013-0018-5 · Cited by 19
Kummer, C., Winkeler, A., Dittmar, C., Bauer, B., Rueger, M. A., Rückriem, B., Heneka, M. T., Vollmar, S., Wienhard, K., Fraefel, C., et al. (2007) · Molecular Imaging · doi:10.2310/7290.2007.00015 · Cited by 17
Safety Assurance for Biologics Manufactured in Mammalian Cell Cultures: A Multitiered Strategy
Chen, D. (2013) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2013_213 · Cited by 4
Adeno-Associated Virus Enhances Wild-Type and Oncolytic Adenovirus Spread
Laborda, E., Puig-Saus, C., Cascalló, M., Chillón, M., & Alemany, R. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.124 · Cited by 4
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 954
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Metadata
- Authors
- Kaufman, H. L., Kohlhapp, F. J., & Zloza, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-09
- Volume
- 14
- Issue
- 9
- Pages
- 642-662
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1913328895
- Cited by
- 1,642
- References
- 160
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.